Increased cell avidity through CD38 co-receptor drives enhanced BCMA CAR T-cell sensitivity and persistence in multiple myeloma
In this research highlight, we present cell avidity results obtained with the z-Movi® Cell Avidity Analyzer in collaboration with the team of Dr. Maria Themeli (VUMC Cancer Center Amsterdam) working on BCMA + CD38 dual-targeting CAR T therapy against multiple myeloma.
Key learning points:
- Cell avidity measurements with the z-Movi lead to rapid screening and identification of new, effective dual-targeting CAR T-cell therapy candidates for multiple myeloma.
- Cell avidity measurements can be used as a tool for the pre-screening of lead CAR products at an early phase by predicting in vitro and in vivo functionality of different CAR T-cell populations.
- Quick characterization of different CAR T-cell populations using an easy workflow.
